Pune, Maharashtra -- (SBWIRE) -- 02/01/2017 -- Charcot-Marie-Tooth Disease Type I A Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Charcot-Marie-Tooth Disease Type I A therapeutics industry report provides comprehensive information on the therapeutics under development for Charcot-Marie-Tooth Disease Type I A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Charcot-Marie-Tooth Disease Type I A and features dormant and discontinued projects.

Charcot-Marie-Tooth disease type 1A (CMT1A) is a type of inherited neurological disorder that affects the peripheral nerves. Symptoms include distal weakness and atrophy, sensory loss, foot deformities, and slow nerve conduction velocity. The disorder is caused by a duplication of the PMP22 gene on Chromosome 17. Symptomatic treatment includes pain medication, physical therapy and surgery.

Browse a Report Copy at: http://www.absolutereports.com/charcot-marie-tooth-disease-type-i-a-pipeline-review-h2-2016-10512152

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Key players in Charcot-Marie-Tooth Disease Type I A – Pipeline Review, H2 2016:

- Addex Therapeutics Ltd
- Affectis Pharmaceuticals AG
- Genzyme Corp
- Lead Discovery Center GmbH
- Pharnext SA

Purchase a Report Copy at: http://www.absolutereports.com/purchase/10512152

Scope Charcot-Marie-Tooth Disease Type I A Pipeline Review Report-

- The pipeline guide provides a snapshot of the global therapeutic landscape of Charcot-Marie-Tooth Disease Type I A (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders)

Key Topics Covered:

1.Introduction

2.Charcot-Marie-Tooth Disease Type I A Overview

3.Charcot-Marie-Tooth Disease Type I A Therapeutics Development

4.Pipeline Products for Charcot-Marie-Tooth Disease Type I A - Overview

5.Pipeline Products for Charcot-Marie-Tooth Disease Type I A - Comparative Analysis

6.Charcot-Marie-Tooth Disease Type I A - Therapeutics under Development by Companies

7.Charcot-Marie-Tooth Disease Type I A - Therapeutics under Investigation by Universities/Institutes

8.Charcot-Marie-Tooth Disease Type I A Products Glance

9.Late Stage Products

10.Clinical Stage Products

11.Early Stage Products

12.Charcot-Marie-Tooth Disease Type I A - Products under Development by Companies

13.Charcot-Marie-Tooth Disease Type I A - Products under Investigation by Universities/Institutes

14.Charcot-Marie-Tooth Disease Type I A - Companies Involved in Therapeutics Development

15.Charcot-Marie-Tooth Disease Type I A Drug Profiles

16.Charcot-Marie-Tooth Disease Type I A Dormant Projects

17.Charcot-Marie-Tooth Disease Type I A Discontinued Products

18.Charcot-Marie-Tooth Disease Type I A Featured News & Press Releases

Sample PDF of Charcot-Marie-Tooth Disease Type I A Pipeline Review H2 2016 Research Study at: http://www.absolutereports.com/enquiry/request-sample/10512152

This research study help to:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Charcot-Marie-Tooth Disease Type I A (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Charcot-Marie-Tooth Disease Type I A (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Ask Discount on Charcot-Marie-Tooth Disease Type I A Therapeutics Companies Review H2 2016 Research Report at: http://www.absolutereports.com/enquiry/request-discount/10512152

About Absolute Report
Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.